STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within 6-24 Hours or Rescue Coronary Intervention Versus a Strategy of Standard Primary PCI in Patients With Acute Myocardial Infarction Within 3 Hours of Onset of Symptoms.
Phase of Trial: Phase III
Latest Information Update: 17 Feb 2015
At a glance
- Drugs Tenecteplase (Primary) ; Aspirin; Clopidogrel; Enoxaparin sodium; Enoxaparin sodium
- Indications Cardiovascular disorders; Myocardial infarction
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms STREAM
- 11 Mar 2013 Data presented at the American College of Cardiology 62nd Annual Scientific Sessions and Expo, according to a Boehringer Ingelheim media release.
- 10 Mar 2013 Primary endpoint `composite of all-cause mortality, cardiogenic shock, congestive heart failure and recurrent myocardial infarction' has been met.
- 10 Mar 2013 Rationale, trial design and results presented at a late-breaking clinical trial session at the 62nd Annual Scientific Session of the American College of Cardiology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History